【medical-news】拜耳新型低剂量口服避孕药将在欧
Bayer Schering Pharma's new low-dose oral contraceptive Yaz(R) (drospirenone/ethinylestradiol) has been approved in the European Union. Once launched, it will be the first oral contraceptive on the European market containing the progestin drospirenone combined with a low dose of ethinyl estradiol in a new dosing regimen of 24 days of active hormone tablets and four days of placebo. Yaz(R) will be launched in all major European markets in autumn 2008. It has been available since 2006 in the U.S., where it is approved for three distinct indications: contraception, treatment of moderate acne and treatment of the emotional and physical symptoms associated with PMDD (premenstrual dysphoric disorder), such as mood swings, irritability, anxiety, food cravings, breast tenderness, bloating and headache. Bayer Schering Pharma also plans to submit the Yaz(R) acne and PMDD indication for registration in Europe
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-04 05:11
医学,生命科学网
